La cadena de opciones muestra datos clave de las opciones de acciones de Ensysce Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Ensysce Biosciences..

Ensysce Biosciences (NASDAQ:ENSC) Bolsa, Cadena de Opciones

Ensysce Biosciences

Ensysce Biosciences Inc

Ensysce Biosciences Inc Warrants (05/12/2019)

AIM ImmunoTech

Aprea Therapeutics

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Galecto

GT Biopharma

HCW Biologics

IN8bio

Kala Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Oragenics

Polyrizon

PharmaCyte Biotech

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revolution Medicines

SILO Pharma

Theriva Biologics

VivoSim Labs

Xenetic Biosciences

Ensysce Biosciences (ENSC) Previsión

Noticias

Beneficios

Calificaciones de analistas

Operaciones de insiders

Interés en corto

Informe de acciones

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Comments

Ensysce Biosciences Cadena de Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL